title: Glasgow Prognostic Score Predicts Clinical Outcomes in Patients with Pancreatic Cancer Undergoing Adjuvant Gemcitabine Monotherapy After Curative Surgery.
abstract: OBJECTIVE
  The Glasgow Prognostic Score (GPS), an inflammation-based prognostic score, has been shown to predict the clinical outcomes of a variety of cancer types. The aim of this study was to determine whether the GPS predicts clinical outcomes of patients with pancreatic cancer treated with adjuvant chemotherapy after surgery.
  
  
  METHODS
  Forty patients resected for pancreatic cancer who underwent adjuvant gemcitabine monotherapy after curative surgery were included. The GPS was measured prior to adjuvant therapy and correlated with clinical outcomes.
  
  
  RESULTS
  The disease-free survival (DFS) and overall survival (OS) in patients with an elevated GPS (GPS1 or GPS2) were significantly poorer (p=0.001 and p=0.035, respectively, by log-rank test) than patients with a GPS of 0. An elevated GPS was found to be independently associated with poor DFS (p=0.002, by Cox regression model).
  
  
  CONCLUSIONS
  The pre-adjuvant GPS may predict clinical outcome in patients with pancreatic cancer undergoing adjuvant chemotherapy after surgery.
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan morinagas@kcch.jp.
authors.forename: Soichiro
authors.initials: S
authors.lastname: Morinaga
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Murakawa
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Katayama
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Yamaoku
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Aoyama
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Amane
authors.initials: A
authors.lastname: Kanazawa
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Akio
authors.initials: A
authors.lastname: Higuchi
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Manabu
authors.initials: M
authors.lastname: Shiozawa
authors.affiliation: Department of Gastrointestinal Medicine, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kobayashi
authors.affiliation: Department of Gastrointestinal Medicine, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Ueno
authors.affiliation: Department of Gastrointestinal Medicine, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Manabu
authors.initials: M
authors.lastname: Morimoto
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D011379:Prognosis; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D000093542:Gemcitabine
keywords: Glascow prognostic score; clinical outcome; curative surgery; gemcitabine monotherapy; pancreatic cancer